Enveric Biosciences to Join BIO International Convention 2024

Enveric Biosciences, a biotechnology firm listed on NASDAQ with the ticker symbol ENVB, is focused on developing innovative neuroplastogenic small-molecule therapeutics aimed at treating mental health disorders such as depression, anxiety, and addiction. The company recently announced its participation in the 2024 BIO International Convention, which will be held in San Diego, California from June 3 to June 6, 2024.

During the event, Enveric’s leadership team intends to meet with potential investment and development partners to explore collaboration opportunities for their promising drug candidates. Joseph Tucker, Ph.D., who serves as the Director and Chief Executive Officer of Enveric, expressed optimism about the interest from potential strategic partners in the pharmaceutical industry. He highlighted the significance of the company's drug discovery engine in generating assets that attract interest for potential partnerships.

Enveric Biosciences leverages its proprietary discovery and development platform, Psybrary™, to create a substantial intellectual property portfolio consisting of new chemical entities tailored for specific mental health conditions. The company’s lead program, EB-003, represents a first-in-class approach to treating challenging mental health disorders by promoting neuroplasticity without causing hallucinations in patients. Another key program, EB-002 (formerly known as EB-373), involves a next-generation synthetic prodrug of psilocin, which is being investigated as a treatment for psychiatric conditions.

Enveric’s operations are headquartered in Naples, Florida, with additional offices located in Cambridge, Massachusetts, and Calgary, Alberta, Canada.

The press release also contains forward-looking statements that discuss potential future events or performance. Forward-looking statements can often be identified by terms such as "plans," "expects," "proposed," "budgets," "explores," "scheduled," "seeks," "estimates," "forecasts," "intends," "anticipates," or similar phrases. These statements reflect the beliefs and assumptions of Enveric’s management based on information currently available to them. However, actual results may differ significantly from those projected due to various risk factors and uncertainties.

Some of the specific risks mentioned include the ability to negotiate and finalize definitive agreements based on out-licensing term sheets, the success of clinical programs in Australia, and the validation of efficacy and safety in clinical trials. Other potential challenges include obtaining necessary governmental approvals, securing future funding, scaling up product manufacturing, responding to competitive pressures, hiring and retaining key personnel, and protecting intellectual property rights.

Enveric also underscores the importance of managing its growth effectively and continuing as a going concern. The company commits to revising forward-looking statements only as required by law, avoiding any obligation to update them based on new information or future events.

Enveric’s filings with the Securities and Exchange Commission, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, provide further insights into these risks and uncertainties.